VYNE Therapeutics Inc. (VYNE) analyst actions
Rating and price-target actions on VYNE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VYNE overview →
1 measured VYNE analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis | Press release | — | +1.61% |
Keep exploring
More VYNE: earnings → · SEC filings → · VYNE overview →